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ABSTRACT 
The relationship between urinary dopamine levels and arterial blood 
pressure was studied in normal, unilaterally nephrectomized, and renal 
hypertensive male albino rats. 
Experimental hypertension was produced by a unilateral nephrectomy 
followed by compression of the contralateral renal artery. The two operations 
were spaced three weeks apart to allow for recovery. 
Nine weeks after-the-second operatton; mean systolic blood pressure of 
the renal hypertensive control group increased to 170 mm Hg. Mean systolic 
blood pressure of the diethyldithiocarbamate (DDC)-treated renal hypertensive 
group decreased abruptly after two weeks of treatment and remained at 105 mm 
Hg throughout the nine week period. Mean systolic blood pressures of the normal 
and unilaterally nephrectomized group of animals remained between 100-12 5 mm 
Hg throughout the study. However, in comparisons with control groups, the 
systolic blood pressures of the DDC-treated unilaterally nephrectomized and 
normal groups of animals were significantly lower after four or seven weeks 
of treatment respectively. 
Urinary dopamine was extracted by adsorption onto alumina, converted 
to its trihydroxyindole fluorophore and measured spectrofluorimetrically. 
In comparisons with control groups, urinary dopamine levels (µ.g/24 hr, 
µg/kg/24 hr) did not differ significantly in either the normal or DDC-treated 
renal hypertensive group of animals. Mean dopamine levels remained relatively 
constant throughout the nine week period and varied from 15 to 27 µg/24 hr and 
13 to 21 µg/24 hr in the normal and renal hypertensive group of animals 
respectively. Mean dopamine levels varied from 35 to 45 µg/kg/24 hr and 23 
to 26 µg/kg/24 hr in the normal and renal hypertensive groups respectively. 
After seven weeks of treatment, the mean urinary dopamine levels 
(µg/24 hr) of the DDC-treated unilaterally nephrectomized group of animals 
were significantly higher than controls. Mean dopamine levels of the DDC-
treated group increased fro m 11 µg/24 hr to 23 µg/24 hr after the seventh week 
· -
of treatment. The control group remained relatively constant (15 µg/24 hr) 
within the same period. 
Mean body weights of the DDC-treated animals were significantly 
lower than controls after six, four, and two weeks of treatment in the normal, 
unilaterally nephrectomized, and renal hypertensive groups respectively. 
In all groups of drug-treated animals there was a correlation between 
decreased body weight, decreased amount of functional kidney tissue, and 
decreased arterial blood pressure. No correlation was found between art~rial 
blood pressure and urinary dopamine levels. 
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I. INTRODUCTION 
In the treatment of disease, a knowledge of the physiological and 
metabolic derangements of the disease must first be considered. Only then 
can the treatment be effectively employed. 
Within the last decade many attempts have been made to show a relation-
ship between erroneous catecholamine metabolism and the hypertensive 
disease state. Because of their prominent pressor effects on the cardiovascular 
system, norepinephrine and epinephrine have been the focus of this attention. 
However, their precursor, dopamine, also possesses pressor effects. This 
led to a study by DeFanti and DeFeo (1963) of the role of dopamine in the etiology 
of experimental renal hypertension in male albino rats. These investigators 
reported evidence indicating a positive correlation between arterial blood 
pressure and urinary dopamine concentration in renal hypertensive rats. 
To further investigate the role of dopamine in experimental hypertension, 
the present investigation was designed to inhibit the enzyme dopamine-j3-hydroxy-
lase, the enzyme responsible for the conversion of dopamine to norepinephrine, 
with diethyldithiocarbamate. Evaluation was based on the effect of this drug on 
systolic blood pressure, weight gains, and urinary dopamine levels in renal 
hypertensive, unilaterally nephrectomized, and normal male albino rats. 
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II. REVIEW OF THE LITERATURE 
In recent years much attention has been focused on the role of cate-
cholamines in the pathogenesis of arterial hypertension. Suspected aber-
rations of catecholamine metabolism have led investigators to study the role 
of circulating catecholamines and their metabolites during hypertension. 
Interference v.rith the metabolism of these pressor substances could lead to 
an accumulation of one or more of these compounds and conceivably main-
tain a hypertensive state. 
Figure 1 represents the main pathway, first proposed by Blaschko (1939), 
in the formation of the catecholamines. The last three compounds in this 
sequence represent the pressor catecholamines. 
Evidence in support of this pathway was reported by Gurin and Delluva 
(1947) who observed that 14c- and 3H-phenylalanine labeled in the side chain 
and ring respectively was incorporated into adrenal epinephrine (E). Later, 
Langemann (1951) measured the enzyme Dopa decarboxylase in the adrenal 
medulla in rats. Leeper and Udenfriend (l956) administered 14c-3, 4-di-
hydroxyphenylalanine (Dopa) to rats and measured 14c-norepinephrine (NE) 
in the adrenals. It wasn't until 19 57 that Goodall and Kirshner, using 
isotope dilution techniques, demonstrated unequivocally th3_t Blaschko's pro-
posed pathway was correct. Incubation of 14c-tyrosine or 14c-Dopa with 
bovine adrenal slices resulted in the label appearing in dopamine (DA), followed 
by NE and subsequently E. Nagatsu et al. (1964) confirmed the synthetic path-
way with the isolation and characterization of tyrosine hydroxylase. 
Udenfriend (1966) observed tyrosine hydroxylase to be the rate - limiting 
step in NE synthesis, because the amount of enzyme was limiting. When 
tyrosine, Dopa, or DA was incubated with tyrosine hydroxylase, saturation 
could only be achieved with tyrosine. The V max for Dopa decarboxylase or 
dopamine-(3-hydroxylase (DBH) [3, 4-dihydroxyphenylethylamine, ascorbate: 
oxygen, oxidoreductase, E. C. 1.14. 2.1] was reported as two or three orders 
of mag1utude higher than that for tyrosine hydroxylase. 
5 
I 
OCH2CHNH;:; 
1 
PHENYLALANINE 
HOrA1CHOHCl\NH CH3 
Ho VJ ¢::J 
5 
EPINEPHRINE 
~CH2CHNH2COOH 
HOVJ c:;> 
2 
TYROSINE 
HO rA1~HOHCH2NH2 
HOVJ ¢::J 
4 
NORE PINE PHRINE 
::~H2CHNH2COOH 
DOPA 
~3 
::ocH2c~NH2 
DOPAMINE 
Fig. 1. Main pathway in the biosynthesis of the active catecholamines: 1) phenylalanine 
hydroxylase, 2) tyrosine hydroxylase, 3) DOPA decarboxylase, 4) dopamine-
J3-hydroxylase, 5) phenylethanolamine-N-methyl transferase. 
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Reports that DBH may be the rate-limiting step are conflicting 
(Musacchio et al., 1964; Nikodijevic et al., 1963; Udenfriend et al., 1966). 
With the introduction of more sensitive qualitative and quantitative 
analyses, the identification of the physiological mechanisms of inactivation 
of the catecholamines was confirmed. A short summary of the catabolism 
of the catecholamines appears in Figure 2. 
Evidence that monoamine oxidase {monoamine: oxygen, oxidoreductase, 
E. C. 1. 4. 3. 4] (MAO) oxidizes DA at a more rapid rate than either NE or E 
was presented by Blaschko (1952). This preferential attack appears to be due 
to the lack of the ,B-hydroxyl group on the catecholamine moiety. This report 
suggested that because of the tremendous affinity of MAO for DA, this cate-
cholamine might be the primary physiological substrate for the enzyme. 
Blaschko further speculated that MAO may serve a regulatory role by limiting 
the amount of DA available for metabolism to NE and E. 
7 
Axelrod ~al. (19 57) demonstrated a predominant in vitro 0-methylation 
of the catecholamines E and NE. However, after intraperitoneal injection of 
DA in the rat only 3% of the administered dose was excreted as its 0-methylated 
derivative, 3-methoxytyramine. Pretreatment of the animals with iproniazid, 
an MAO inhibitor, resulted in a five-fold increase of excreted 3-methoxytyr-
amine. These findings suggested that, although E and NE were largely 0-
methylated, DA was metabolized predominantly by MAO. 
This was further substantiated by Goldstein et al. (1959) who administered 
3-hydroxy-1-14c-tyramine to rats and reported 60% of the administered 
radioactivity excreted as 3-methoxy-4-hydroxyphenylacetic acid and 2-3% 
excreted as 3-methoxytyramine. After pretreatment with iproniazid 31 % of 
administered radioactivity was excreted as 3-methoxytyramine and 10% as 
3-hydroxytyramine. 
Additional support that MAO should be the first enzyme involved in the 
catabolism of DA was provided by Carlsson and Waldeck (1964) who reported 
that both the enzyme and DA are concentrated within sympathetic nerve endings. 
MAO ~ 2 COMT ~ OCH COOH ~ IHYDROXYPHENYL ;QH~fHi2NH2 3,4-~CETIC ACID OCHOHCH NH2 
HCHNH CHO 2 CHO C 2 2 2 > 3 
OOP 3 0, . CH OOCHOHCH2NH2 R-0 D 
HO 3 O OONJUGATED nDBH 3--METHOXYTYRAMINE HO . ~ NOR.MET ANEPHRINE v ~ NOHMETANEPHRINE 
' · HorLJriolfCH2NH2 COMT HOO· CHOH~ CH3oocH~cH~~ 
CH~:oCH2COOH 
HOMOVANILLIC ACID 
-7' 
M:IUJ 
OCOOH' ttoiVJ MAO . H<*V VANILLIC NOREPINEPHRINE . ~ H DROXYMANDELIC 4-HYDRQX.Y - 3-:~~XY ACID 
. nPEMT ~ 3,4-DIHY Acin MANDELIC ALD 
v . n . OCHOH~CHNHCH3 HOO. . CHOHCH2NHCH3 
HO . 
I I I -:!'> 
CH30n AO 
H ~ ....___ EPINEPHRINE 
Fig. 2. 
METANEPHRINE 
Catabolism of dopamine, norepinephrine, and epinephrine. Heavy arrows indicate 
CH 00 CHOHCH NH 3 • 21 2 
R-0 CH 
3 
CONJUGATED 
METANEPHRINE 
main catabolic pathway, other arrows indicate alternate pathway of catecholamine 
destruction. Catechol-0-methyl transferase (COMT), monoamine oxidase (MAO), dopamine-
{3-hydroxylase (DBH), phenylethanolamine N-methyl transferase (PEMT). 
00 
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Reports relating catecholamine levels and arterial hypertension have 
been sparse arrl equivocal. Von Euler (1956) reported no significant 
difference in NE levels when hypertensive subjects were compared to normals. 
Alternatively, a two-fold increase in NE and E and a five-fold increase in DA 
was observed in hypertensive patients by Weil-Malherbe and Bone (1957). 
These authors also observed a greater variation in daily DA excretion than 
with either NE or E. 
Peart (1966) observed that there is hardly any evidence of credit which 
· associates increased circulating catecholamines with hypertension. This 
suggests, therefore, that, if a relationship does exist, some change in synthesis, 
degradation, storage, release, or sensitivity of the vasculature to NE and E 
may exist. However, this author also suggests that sympathetic tone is 
normal in hypertension. 
Studies into the possiblity of an altered turnover rate of any of the cate-
cholamines during the hypertensive disease have been sporadic (Gitlow et al. , 
1964; Sjoerdsma et al., 1961; Mendlowitz et al. , 1959). 
Although DA has been sho\vn to possess vasoactive properties, this cate-
cholamine has been largely ignored as a possible participant in hypertension. 
Dependent on the route of administration, DA has been reported as a pressor 
agent in the cat (Holtz et al., 1962), dog (Holmes and Fowler, 1962), man 
(Horwitz et al., 1962) and in the rat (Holtz et al., 1962; Pogrund et al., 1961). 
In most cases the pressor response was a result. of increased cardiac output 
with little or no change in peripheral resistance observed. 
Reports of the distribution of. DA in mammalian tissues have been con-
flicting. Schumann (1959) reported a wide distribution of DA in various tissues 
in the rat, whereas Wegmann (1963) could detect the presence of DA only in the 
spleen and kidney of the dog. DA could not be found in the plasma of humans, dogs, 
or rabbits (Anton and Sayre, 1964; Carlsson, 1959). 
Bing (1941) reported evidence for the production of a pressor substance, 
presumably DA, from the decarboxylation of Dopa in extracts of guinea pig 
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kidneys under anerobic conditions. He observed a similar reaction in vivo in 
cat's ischemic kidney perfused with blood containing Dopa. This report 
suggests that deamina:tion but not decarboxylation of amino ·acids is incomplete 
in anoxic kidneys. This possibility was verified by Giordano et al. (1959), who 
observed increased kidney Dopa decarboxylase and decreased kidney MAO 
after prolonged hypertension in rabbits with renal ischemia. These altered 
enzyme levels could conceivably lead to an accumulation of DA, NE, and/or 
E in ischemic tissue. 
DeFanti and DeFeo (1963) r~ported evidence indicating a positive 
correlation between arterial blood pressure and urinary DA concentration in 
renal hypertensive rats. 
These studies suggested that decreased MAO activity in the ischemic 
kidney results in an excess of DA in the tissues. The established pressor 
activity of DA in man and animal and the reported increase in urinary DA 
in the hypertensive rat suggested a role for DA in hypertensive disease. 
If, under these conditions of decreased MAO activity, the enzyme 
responsible for the conversion of DA to NE were inhibited by the use of 
drugs, the excess DA present might result in an increased arterial pressure. 
DBH, the enzyme responsible for the conversion of DA to NE, has been 
reported to be inhibited by two classes of drugs. Analogs of the natural 
substrate DA, with the a-carbon atom substituted with either Nor 0, proved 
to be very potent competitive inhibitors of the active site on the enzyme 
(Creveling et al., 1962). Although effective in vitro, the compounds in vivo 
were hydrolyzed at a slow rate resulting in false transmitters with little or 
no DBH inhibiting activity. 
DBH has been shown to require copper as a cofactor in a concentration 
of 0.65 to 1. 0 µg per mg of enzyme (Friedman and Kaufman, 1965). Binding 
of the copper by drugs could inactivate this enzyme. 
Disulfiram and one of its reduced metapolites, diethyldithiocarbamate 
(DDC), belong to this second class of DBH inhibitors and have -been reported 
11 
to inhibit this enzyme in vivo (Goldstein and Anagnoste et al., 1964; Goldstein 
and Lauber ~al., 1964). Goldstein and Anagnoste ~al. (1964) have observed 
a 100% inhibition of DBH with 10-5M DDC in vitro. Musacchio et a.I. (1966) 
reported that DDC prevented the conversion of DA-H3, tyramine-H3 and other 
phenylethylamines to their ,B-hydroxylated analogs. Increased DA levels with 
a simultaneous decrease in NE in rat and rabbit small intestine have been 
demonstrated by Collins (1965). Carlsson et al. (1966) could not verify this 
change in ileum tissue but did observe a significant change in the adrenals 
and brain stem of the rat. 
The findings of DeFanti and DeFeo (1963), the reported pressor activity 
of DA in man and animal, and the availability of a suitable DBH inhibitor suggest 
the need for further study into the possible role of DA in renal hypertension. 
ill. INVESTIGATION 
A. Objectives 
The possibility that 3-hydroxytyramine (dopamine) was implicated in 
renal hypertension was suggested by DeFanti and DeFeo (1963). They reported 
a positive correlation between the increased arterial blood pressure and urinary 
dopamine concentration in renal hypertensive rats. The objectives of this 
study were to determine if there was an increase in the urinary excretion of 
dopamine in rats rendered hypertensive by renal ischemia and if the increased 
arterial blood pressure was significantly dependent upon an increase in dopamine. 
B. Materials and Methods 
1. General Considerations and Daily Protocol 
Adult male albino rats of the Sprague-Dawley strain1 weighing125-150 g 
were divided into three groups: surgically intact, unilaterally nephrectomized, 
and renal hypertensive. Each group was further divided into two sub-groups: 
animals receiving sodium diethyldithiocarbamate2 (66. 5 mg/kg) and animals 
receiving the vehicle, 0.1 M phosphate buffer (pH 7. 4) 1 ml/kg. All animals 
were injected on alternate days and housed in a room lighted from 7:00 a. m. to 
7:00 p. m. and maintained at 22 ± O. 5° C. Purina 3 rat chow and water were 
provided ad libitum. Student's "t" test (Snedecor, 1956) was used for all com-
parisons reported. 
2. Production of Experimental Hypertension 
Experimental renal hypertension was induced by the method of Goldblatt 
et al. (1934) as modified by Drury (1938). The method consisted of a unilateral 
nephrectomy followed by compression of the right renal artery. The two opera-
tions were spaced three weeks apart to allow for the recovery of the animals. 
1. Charles River Breeding Farms, North Wilmington, Massachusetts. 
2. J. T. Baker Chemical Company, Phillipsburg, New Jersey. 
3. Ralston Purina, St. Louis, Missouri. 
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The unilateral nephrectomy was performed on the right kidney by making 
a dorsolateral incision an inch in length parallel to the spinal cord. The 
kidney was palpated and located retroperitoneally to the abdominal cavity and 
laterally to the incision. The organ was forced through the incision and 
exposed for ligation with nylon thread. The artery, vein and ureter were 
ligated; the organ was then excised and frozen in liquid nitrogen for later 
analysis. The adrenal gland remained intact. The incision through the muscle 
was closed with 3-0 silk suture and the epidermal incision closed with stainless 
steel wound clips. 
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Approximately three weeks after the first operation the left renal artery 
was located by making a one inch ventrolateral incision in the lower abdominal 
area. The artery was separated from the renal vein, and a stylet approximately 
one third the size of the artery was placed parallel to the vessel. A nylon suture 
was looped around both stylet and vessel and secured. The stylet was withdrawn 
allowing the artery to expand to one-third of its normal size. The incision was 
closed in the manner previously mentioned. All animals were fasted for 
twenty-four hours prior to both operations to facilitate operative procedures. 
3. Blood Pressure Measurement 
The systolic blood pressure of all animals was monitored on a bi-weekly 
basis using the tail cuff method (Coates, 1968). The method utilizes an in-
flatable tail cuff placed about one centimeter from the base of the tail and con-
nected to a Physiograph1 manometer system. The tail was passed through a 
holder to brm'g it into contact with a Beckman2 microphone transducer which 
was connected to an Infraton2 signal divider adjusted for maximum pulse. This 
lead was then connected to an HP oscilloscope 3. As the cuff was inflated, cir-
culation stopped, and no pulses were transferred to the oscilloscope. Con-
versely, as the cuff was deflated, the circulation was restored, and, at the 
point where pulses reappeared, the impulses were observed on the oscilloscope 
1. E & M Instruments, Houston, Texas. 
2 . Beckm an Co., Palo Alto, Californi a . 
3. Model 130 B., Hewlett-Packar d Co., P~l-10 Alto, California. 
and the pressure read on the manometer. Each value was the mean of three 
separate determinations spaced a minute apart. 
4. Weight Gain Measurement 
The effects of treatment with drug and vehicle on the individual body 
weights of the animals were determined. All animals were weighed to the 
nearest gram at the time of injection on an Ohaus small animal balance 1 . The 
individual weights of the drug-treated animals were compared with the weights 
of the control group on a bi-weekly basis. 
5. Collection of Urine 
The animals from each group were selectively paired in an effort to house 
animals of similar weights. Urine samples passed through stainless steel 
funnels were collected over O. 5 ml of concentrated sulfuric acid. The acid 
hydrolyzed any conjugated dopamine and maintained an acid pH to avoid auto-:-
oxidation to 6-0H dopamine. The samples were stored in test tubes at -4o0 c 
for later analysis. 
6. Extraction of Urine 
The urine samples were centrifuged for twenty minutes, and 10 ml of the 
supernatant was decanted into a clean test tube. Two ml of O. 2 M disodium 
ethylenediamine tetraacetate was added to the sample with two drops of concen-
trated hydrochloric acid. The samples were boiled for twenty minutes and 
cooled. The samples were then adjusted to pH 8. 4 with 1 N NaOH, and 1 ml 
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of an antioxidant (sodium metabisulfite 10 mg/ml) was added. The samples were 
passed through a column prepared by the addition of aluminum oxide2 suspended 
in 10 ml of 0.1 M ammonium acetate buffer, pH 8, and 0. 28 ml 0.1 N NaOH. 
The alumina used was a chromatographic quality. The column had an inside 
diameter of 0. 6 cm and a length of 7. 5 cm. The flow rate was adjusted to 
1. Ohaus Scale Corporation, Union, New Jersey. 
2. British Drug Houses, LTD; exclusive United States Distributors Gallard-
Schlesinger Manufacturing Corp. , Long Island, New York. 
15 
2 ml/min. by a Hoffman clamp. Bertler et al. (1958) have demonstrated 
+ 
that Dopa ·will readily pass through the Na form of the alumina. Since Dopa 
has the same fluoresc'ence characteristics as ~opamine, it was desirable to 
pass a 5 ml portion of sodium acetate 0.1 M through the column, prior to elution 
to eliminate any contaminating Dopa. The samples were eluted by two 5 ml 
portions of 0. 2 N acetic acid. 
7. Development of Sample 
Development procedure was carried out at room temperature according 
to the method of Carlsson and Waldeck (1958) as modified by Coates (1968). A 
3 ml aliquot of the eluate was adjusted to pH 6. 5 with the addition of 1 ml of O. 3M 
potassium carbonate. The samples were treated with 1 ml of 0.1 M phosphate 
buffer pH 6. 5 and the volumes diluted to 7 ml with glass distilled water. Two 
drops of a O. 25 M iodine solution were added to each sample. Three minutes 
after the addition of iodine, 1 ml of alkaline sulfite reagent (500 mg sodium 
sulfite. 7 H20 per ml water diluted to 10 ml with 5N NaOH) were added to the 
samples. After four minutes, 1 ml of 6 N acetic acid was added to all samples. 
The samples were diluted to 10 ml with glass distilled water, boiled for 10 
minutes and the supernatant decanted to quartz cuvettes. The cuvettes were 
irradiated at 253 mµ in ultraviolet light1 for ten minutes to sustain fluorescence. 
The sample fluorescence was measured at 370 mµ on an Aminco-Bowman spectro-
photofluorometer2. Activation wavelength was 325 mµ (uncorrected instrument 
values). A tissue blank which contained a 3 ml eluate aliquot was prepared and 
assayed as above, except that 4. 5 N NaOH was substituted for the alkaline sul-
fite reagent. Two drops of a sodium sulfite solution (500 mg/ml) were added 
prior to centrifugation to remove the remaining iodine color to avoid quenching. 
A standard curve of known dopamine concentration was obtained with each set 
of samples. A linear relationship between fluorescence and dopamine concen-
tration as reported by Carlsson and Waldeck (1958), DeFanti (1961), and 
1. Chromato-Vue, Black Light Eastern Corp., New York, New York. 
2. American Instrument Co., Inc., Silver Springs , 1\lar yland. Slit Arrange-
ment number 3. Fused qun.rtz cells were used. 
Coates (1968) was found to exist up to 0. 5 µg/ml of dopamine (Figure 3). 
An estimate of the dopamine content was made by dividing the corrected 
fluorescent intensities of the unknowns by a value calcuaited to represent the 
fluorescent intensity of a solution of dopamine containing 0.1 µg/ml. The 
fluorescent intensity contributed by the reagents was subtracted from the 
fluorescent intensity o~ the standard solutions. The corrected values were 
adjusted and averaged to obtain a single value which represented the fluorescent 
intensity of a 0.1 µg/ml solution of dopamine. Coates (1968) summarizes the 
mechanics as follows: 
0.1 I I =(F -R.B.x-c ) n s s 
Where I = fluorescent intensity of a 0.1 µg/ml solution of dopamine 
s 
F s = uncorrected fluorescent intensity of the developed solutions at 
concentration C 
R. B. = fluorescent intensity of the reagent blank 
C = final concentrations of dopamine in µg/ml 
n = the number of determinations 
and finally: 
Where C 
u 
F 
u 
Bu 
I 
s 
= 
= 
= 
= 
C = (F -B ) /I 
u u u s 
the concentration of dopamine (µg/ml) in the developed solution 
of the unknown 
the uncorrected fluorescence intensity of the developed solution 
of the unknown 
the fluorescent intensity of corresponding blank of the unknown 
the fluorescent intensity of the standard as determined above 
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Since the final volume of the developed solutions was 10 ml, the total 
dopamine content of a 3 ml column aliquot was equivalent to l _O times the concen-
Fig. 3. Fluorescence intensity at varying concentrations of dopamine. 
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tration in µg/ml (10 C ) and the total in a 10 ml eluate to 100 C /3. The total 
u u 
amount of dopamine in a sample was then calculated by the use of the follO'wing 
formula: 
Where Dt = the total qua.µtity {µg) of dopamine in a sample 
V 1 = the volume (ml) of the sample extracted for dopamine content 
V 2 = the total volume (ml) of the sample 
Cu = the concentration of dopamine {µg/ml) in the developed solution 
of the unknown 
This method of dopamine determination provided accurate recoveries. 
The average recovery obtained for knovvn concentrations of dopamine from 
+ 0.2 N acetic acid was 88.2 - 6. 5%, (Table I). 
Throughout the experimental period internal standards (known amounts 
of dopamine added to the urine prior to processing) were determined at 
selected intervals. The mean recovery was 84. 3 : 8. 7% (Table II). 
18 
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Table I 
Percent recovery of dopamine from O. 2 N acetic acid 
Dopamine added (µg) Dopamine fotind (µg) % Recovery 
2.00 1. 68 84. 0 
2.00 1. 85 93.0 
2.00 1. 80 90.0 
2.00 1. 83 91. 3 
2.00 1. 38 69.0 
2.00 1. 85 92. 5 
4.00 3. 56 89.0 
4.00 3.74 93.5 
4.00 3.90 97.5 
4.00 3. 51 87.8 
4.00 3.61 86.3 
4.00 3.69 88.1 
6.00 5.45 90.8 
6.00 5. 71 95.1 
6.00 5.49 91. 5 
6.00 4.76 79.2 
6.00 5. 47 87.1 
6.00 4. 95 83. 0 
Mean recovery + standard deviation = 88.2 ~ 6. 5% -
Table II 
Percent recovery of dopamine added to urine samples 
Endogenous 
dopamine (µg) 
2.29 
1. 33 
2.30 
1. 90 
2.50 
0.93 
3.17 
1. 86 
1.43 
1. 09 
Added 
dopamine (µg} 
2.00 
2.00 
2.00 
2.00 
2.00 
2.00 
2.00 
2.00 
3.00 
4.00 
Total dopamine (µg) 
Calculated Found 
4.29 3. 65 
3.33 2.33 
4.30 3.78 
3.90 2.97 
4.50 4.20 
2.93 2. 53 
5.17 4.23 
3.86 3.90 
4.43 3.60 
5.09 4.09 
Mean recovery ~ standard deviation = 84. 3 ~ 8. 7% 
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% 
Recovery 
88 
70 
86 
76 
93 
86 
81 
101 
81 
80 
IV. RESULTS 
The effect of DDC on mean body weight in normal male albino rats is 
illustrated in Fig. 4. The mean body weight of the vehicle-treated animals 
increased over a ten week period from an initial 180 g. to a final weight of 
400 g. At the end of ten weeks of treatment the mean body weight of the 
DDC-treated animals had increased to 350 g. The drug-treated animals had a 
significantly lower mean body weight than vehicle-treated animals after six 
weeks of treatment with DDC. 
Fig. 5 represents the effect of DDC treatment on body weight in unilater-
ally nephrectomized male albino rats. The mean body weight of vehicle-treated 
animals increased from 240 g. to 350 g. during the nine week study. The mean 
body weight of the DDC-treated animals increased from 230 to 300 g. during the 
same period. There was a significant difference in body weight observed after 
four weeks of treatment when DDC-treated animals were compared to controls. 
The mean body weight of vehicle-treated versus DDC-treated renal 
hypertensive male albino rats appears in Fig. 6. The mean body weight of 
• 
the control animals increased to 450 g., whereas, mean body weight of the 
DDC-treated animals increased to 375 g. after ten weeks of treatment. The 
difference from control values became significant after two weeks of treatment 
with DDC. 
The method used to initiate renal hypertension proved successful. After 
nine weeks of treatment the mean systolic blood pressure of the vehicle-treated 
animals increased to 165 mm Hg (Fig. 9). The mean pressure of the surgically 
intact and unilaterally nephrectomized groups of vehicle-treated animals re-
mained relatively constant throughout the same period (Fig. 7 ,-8). 
The effect of DDC treatment on systolic blood pressure in normal male 
albino rats appears in Fig. 7. On the seventh week of treatment with DDC the 
drug-treated animals had a significantly lower mean systolic blood pressure 
when compared to vehicle-treated controls. At the end of eight weeks of treat-
ment the pressure of the veh.icl0- treated animals had in creas~cl from 115 to 125 
mm Hg whereas that of the DDC- tr eatcd animals de ere ascd fro n1 115 to : 1 •• m m Hg. 
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FIG. 8 THE EFFECT OF SODIUM DIETHYLDITHIOCARBAMATE ON 
SYSTOLIC BLOOD PRESSURE IN UNILATERAL NEPHRECTO-
MIZED MALE ALBINO RA TS. 
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The systolic blood pressure of the unilaterally nephrectomized vehicle-
treated male albino rats increased from a mean of 100 mm Hg after seven weeks 
of treatment (Fig. 8). A decrease in systolic blood pressure was observed in 
the drug-treated unilaterally nephrectomized animals ranging from an initial 
mean value of 110 mm Hg to a mean of 98 mm Hg after seven weeks of treat-
ment with DDC. The decrease in systolic blood pressure became significant 
after the fourth week of treatment. 
The hypotensive effect of DDC was more dramatic in renal hypertensive 
animals (Fig. 9). The mean systolic blood pressure of the vehicle-treated 
renal hypertensive male albino rats increased from an initial value of 135 mm Hg 
to a final value of 165 mm Hg. However, the mean systolic blood pressure of 
the DDC-treated animals decreased from a mean of 140 mm Hg initially to 100 mm 
Hg after nine weeks of treatment. A significant difference from controls was 
observed after four weeks of treatment with DDC in the renal hypertensive animals. 
The effect of DDC treatment on urinary dopamine levels in normal male 
albino rats is represented in Fig. 10. There was no significant difference 
observed between control and DDC-treated animals at any time during treatment. 
Urinary dopamine levels of the vehicle-treated animals ranged from an initial 
value of 22 µg/24 hr to a value of 20 µg/24 hr after nine weeks of treatment. 
Similarly, urine dopamine levels of the DDC-treated animals ranged from a low 
of 20 µg/24 hr _after two weeks of treatment to a high of 28 µg/24 hr after six weeks 
of treatment, returning to normal after nine weeks of treatment. 
Fig. 11 represents the effect of DDC on urinary dopamine in unilaterally 
nephrectomized male albino rats. Urinary dopamine levels of the DDC-treated 
animals increased from 18 µg/24 hr to 22 µg/24 hr after seven weeks of treat-
ment. The mean urine dopamine levels of the controls decreased from a normal 
of 15 µg/24 hr to 13 µg/24 hr after the same length of treatment. There was a 
significant difference between drug-treated and control animals observed after 
seven weeks treatment with DDC. 
The effect of DDC on urinary dopamine levels in renal hypertensive male 
albino r a ts appears in Fig. 12. Mean urine dot1;_m1u1e level s of the cont r ols 
increaser! fr o rn 15 µg / 24 hr to 'l ' 1i.., f1 of 18 ~1g/:24, hr af tec n ·~ le weeks of treat-
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FIG. 11 THE EFFECT OF SODIUM DIETHYLDITHIOCARBAMA TE ON 
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ment, whereas the total urinary dopamine of the DDC-treated animals ranged 
from 20 µg/24 hr to a low of 17 µg/24 hr after nine weeks of treatment with 
DDC. There was no significant difference from controls observed at any time 
during treatment. 
Urinary dopamine levels expressed as micrograms per kilogram of body 
weight per 24 hours in normal animals are represented in Fig. 13. Dopamine 
levels (µg/kg/24 hr) varied widely in the DDC and vehicle-treated normal 
animals. There was a tendency of the dopamine concentration of all animals to 
decrease with decreasing weight, however, this trend proved to be statistically 
insignificant. 
Urine dopamine levels (µg/kg/24 hr) in the unilaterally nephrectomized 
group of animals decreased from 33 to 22 µg/kg/24 hr in the vehicle-treated 
group. After seven weeks of treatment with DDC, the urine dopamine levels 
of the drug-treated group of animals decreased from 38 to 34 µg/kg/24 hr 
becoming statistically significant from controls after the seventh week. 
The urinary excretion of dopamine per kg per 24 hr did not differ signifi-
cantly when renal hypertensive drug-treated animals were compared with vehicle-
treated renal hypertensive animals. The dopamine levels of the latter group in-
creased from 21 µg/kg/24 hr to 24 µg/kg/24 hr whereas the urinary dopamine 
excretion of the DDC-treated group decreased from 26 µg/kg/24 hr to 23 µg/ 
kg/24 hr. (Fig. 15) 
FIG. 13 THE EFFECT OF SODIUM DIETHYLDITHIOCARBAMATE ON 
URINARY DOPAMlliE IN MALE ALBINO RATS. (µg/kg/24 hr) 
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V. DISCUSSION 
The time interval subsequent to initiation of treatment at which the body 
weight of the DDC-treated animals became significantly different from that of 
the controls appeared to reflect the am0tmt of functional kidney tissue in the 
three groups of animals studied. This correlation was based on the assump-
tion that a smaller number of nephrons were functional in r enal hypertensive 
and unilaterally nephrectomized than in the normal animals. The unilaterally 
nephrectomized and renal hypertensive DDC-treated animals showed a sig-
nificantly lower body weight than that of the control animals afte:r four and two 
weeks of treatment, respectively. The normal or surgically intact animals 
showed this difference after six weeks of treatment with DDC. This effect 
may be due to a deficiency in detoxication or excretion as a result of decreased 
functional kidney tissue thereby causing a cumulative effect. 
The significant hypotensive effect observed in the three groups treated 
with DDC agrees with the observations of Wohl et al. (1965). These authors 
using desoxycorticosterone acetate-hypertensive rats noted a marked and 
sustained hypotensive effect when 100 mg/kg of disulfiram was administered 
intraperitoneally. An explanation of the hypo tensive effect on the basis of 
increased circulating or tissue dopamine levels appears incongruous to the 
findings of Pogrund et al. (1961), who demonstrated a pressor response to 
dopamine in the rat. However, Thoenen~ al. (1967) observed that after 
inhibition of dopamine-/j-hydroxylase by disulfiram, dopamine incompletely 
replaced the missing norepinephrine suggesting the affinity of dopamine for 
storage sites is weaker than that · of norepinephrine. This view appears to be 
in agreement with the observations of Burn and Rand (1958). These authors 
in an effort to explain the depressor effect of dopamine in guinea pig hypo-
thesized that dopamine, when present in larger quantities than norepinephrine, -
occupied some of the vacated norepinephrine receptor sites. But, being a much 
feebler constrictor agent, dopamine's occupation of the sites results in a loss of 
vascular tone. This supports the belief that the hypotensive effect observed in 
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the DDC-treated animals in this study may be a consequence of decreased 
norepinephrine levels. 
37 
An inability to demonstrate increased urinary dopamine levels with the 
DDC-treated animals appears contradictory to the explanation of the hypo-
tensive effect. However, dopamine has been reported to be the natural 
substrate for MAO (Blaschko, 19 52). Since norepinephrine levels are de-
pressed in DDC-treated animals, excess MAO would be available to metabolize 
circulating or tissue dopamine. Although dopamine and norepinephrine con-
centrations were not measured in the kidney tissues, it would appear that the 
dose of DDC administered was not sufficient to cause a large enough increase 
in circulating dopamine to overcome the available MAO. As a result a signifi-
cant increase in urinary dopamine could not be detected. 
DeFanti and DeFeo (1963) reported finding a positive correlation between 
increased excretion of dopamine (µg/kg/24 hr) and body weight (g.) for renal 
hypertensive rats. However, a decrease in dopamine excretion was observed in 
normotensive rats. 
The decreased urinary dopamine (µg/kg/24 hr) observed in normotensive 
rats in the present study agrees with the findings of DeFanti and DeFeo (1963) 
and Leduc (1961). In normotensive DDC-treated animals however, there was a 
tendency of the dopamine levels (µg/kg/24 hr) to increase to a greater degree 
than that of the vehicle-treated animals , thus providing some indication that the 
dopamine levels were increased as a result of the DDC treatment. The slight 
increase noted in the urinary dopamine levels (µg/kg/24 hr) of the vehicle-
treated group of renal hypertensive animals is in agreement with the previously 
mentioned findings of De Fanti. However, this slight increasing trend is not 
enough evidence to warrant implication of dopamine in arterial hypertension. 
Coates (1968) also reported finding no correlation between dopamine levels 
and arterial blood pressure. A possible explanation for the ~iscrepancy between 
the findings in the present study and the observations of DeFanti may be found 
in the assay methods used in the two studies. As mentioned previously, alumina 
was used in the present study for the extraction of dopamine from ur ine , where-
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as DeFanti used Dowex Sodium 50W-X8. Coates (1968) reported finding that 
Dowex resin was extracting a substance with native fluorescence from the urine 
of rats and that the blank (Carlsson and Waldeck, 1958) by quenching this 
fluorescence was resulting in erroneously high urinary dopamine levels. 
Subsequently, by using alumina and altering the blank, this difficulty was 
circumvented in the present study and allowed a more valid evaluation of 
dopamine excretion in the renal hypertensive animals. 
An apparent discrepancy to this explanation was the significant increase 
in urinary dopamine observed in the unilaterally nephrectomized DDC-treated 
group after seven weeks of treatment. An increase in urine volume per 24 hr 
in the drug-treated group might explain the increased excretion of total dopamine, 
however no significant difference was observed in the volume of urine excreted 
from either group. The large increase in dopamine excreted in the .DDC-treated 
group may be explained on tre basis of an inhibition of dopamine-{3-hydroxylase, 
however no such increase was observed in the DDC-treated renal hypertensive 
group of rats, nor in the normal animals. Further investigation into the mean-
ing of and explanation for the increased excretion of dopamine in DDC-treated 
unilaterally nephrectomized rats appears necessary. 
VI. SUMMARY AND CONCLUSIONS 
Normal, unilaterally nephrectomized, and renal hypertensive male albino 
rats were treated with diethyldithiocarbamate, a dopamine-(3-hydroxylase 
inhibitor. Weight gain, systolic blood pressure, and urinary dopamine levels 
were measured in an effort to further investigate the role of dopamine in 
experimental hypertension. A significant hypotensive effect was observed in 
the three groups treated with diethyldithiocarbamate when compared to vehicle-
treated control animals. Mean body weights of the drug-treated rats were 
significantly lower than controls after six, four, and two weeks of treatment 
in the normal, unilaterally nephrectomized, and renal hypertensive groups 
respectively. There appeared to be a positive correlation between decreasing 
body weight, decreased amount of functional kidney tissue, and decreased 
arterial blood pressure. There was no significant difference in urinary dopa-
mine observed between drug-treated and control animals in either the normal 
or renal hypertensive groups. After seven weeks of treatment with diethyl-
dithiocarbamate, a significant increase iri urinary dopamine was observed in 
the unilaterally nephrectomized drug-treated group when compared to controls. 
No further explanation was offered, however, the results of this . study do not 
indicate any correlation between arterial blood pressure and urinary dopamine 
levels. 
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